ClinConnect ClinConnect Logo
Search / Trial NCT06922786

Hemadsorption to Enhance Drug Elimination in Intoxications

Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Apr 3, 2025

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Benzodiazepine Tricyclic Antidepressant Intoxication Hemadsorption

ClinConnect Summary

This clinical trial is exploring a new treatment method for patients who have taken too much of certain medications, specifically benzodiazepines or tricyclic antidepressants, and are experiencing serious symptoms like prolonged unconsciousness. The researchers want to see if a special device called a hemadsorber (cytosorb®) can help remove these drugs from the blood more quickly in patients who are in the Intensive Care Unit (ICU). To participate in the study, patients must be over 18, admitted to the ICU, have a low level of consciousness, and have a specific type of drug intoxication along with certain health factors, such as liver or kidney issues that make it harder for their body to eliminate the drugs.

If eligible, participants can expect to have their blood tested both before and after the hemadsorber is used to measure how quickly the drug levels drop. The study is not yet recruiting patients, and it’s important to note that some individuals, such as those who are pregnant or already on dialysis, will not be able to participate. This trial aims to improve the treatment for drug intoxications and may offer valuable insights into how to better manage these serious conditions in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. older than18 years
  • 2. Admission to ICU
  • 3. GCS \< 8 or requiring Flumazenil 8 hours after hospital admission
  • 4. Having an intoxication with a benzodiazepine or tricyclic antidepressant that we can measure/quantify
  • 5. Having a risk factor for delayed drug elimination defined as either Cirrhosis CHILD B/C or chronic kidney insufficiency KDIGO 3b or worse
  • Exclusion Criteria:
  • 1. Pregnant patient
  • 2. Patients in chronic dialysis before admission
  • 3. Need for mechanical ventilation for other reasons than intoxications (e.g. pneumonia, neurotrauma)
  • 4. Concomitant pathology requiring continued intravenous sedation
  • 5. Known history of seizures
  • 6. Contra-indication to heparin use
  • 7. DNR restricting the use of mechanical ventilation or dialysis

About Universitair Ziekenhuis Brussel

Universitair Ziekenhuis Brussel (UZ Brussel) is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution affiliated with the Vrije Universiteit Brussel, UZ Brussel integrates cutting-edge medical research with high-quality patient care. The hospital's multidisciplinary teams are dedicated to exploring novel therapeutic approaches and contributing to the development of evidence-based treatments, ensuring the highest standards of safety and efficacy in clinical research. With a strong focus on collaboration and knowledge dissemination, UZ Brussel plays a pivotal role in shaping the future of medicine and improving patient outcomes.

Locations

Brussel, Brussels Hoofdstedelijk Gewest, Belgium

Patients applied

0 patients applied

Trial Officials

Michaël Mekeirele, Medical Doctor

Principal Investigator

Universitair Ziekenhuis Brussel

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported